Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Melarsoprol→

Melarsoprol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
494-79-1
Molecular formula
C12H15AsN6OS2
Molecular weight
398.3 g/mol
Drug class
Trivalent organoarsenical antiprotozoalantitrypanosomal agent
Mechanism of action
An arsenical compound that reacts with parasite thiol-containing molecules, particularly trypanothione, disrupting redox homeostasis and essential metabolic enzyme activity in Trypanosoma brucei.
Indications / reported uses
  • Treatment of second-stage (meningoencephalitic) human African trypanosomiasis caused by Trypanosoma brucei rhodesiense, when central nervous system involvement is present and according to WHO/national treatment guidance.

Sources: https://www.who.int/publications/i/item/9789240096035 · https://www.who.int/health-topics/human-african-trypanosomiasis · https://pubchem.ncbi.nlm.nih.gov/compound/Melarsoprol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Melarsoprol Environmental Risk Assessment (ERA) (the Melarsoprol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.